A Study of WX390 in Patients With Advanced Solid Tumors

Recruiting now · Phase 2

Conditions studied: Solid Tumor

In brief

The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are: * PFS, OS, DoR at week 48; * antitumor effects at week 24 and week 48. Participants will be treated with WX390 orally, and follow the efficacy and safety evaluation according to the protocol.

Key facts

Study ID
NCT06117540
Run by
Shanghai Jiatan Pharmatech Co., Ltd
People needed
70
Starts
2021-05-11
Expected to finish
2026-06-12
Last updated by the study team
2024-11-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.